Title: Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption
Abstract: We appreciate Dr Kawada's interest in our recently published study on lifestyle factors and the risk of myeloproliferative neoplasms (MPN).1 First, he suggested that a possible interaction between coffee consumption and smoking should be evaluated, because the two lifestyle factors were both associated with the risk of MPN and the associations were in opposite directions.2 We have conducted additional analyses and found that there is no evidence of interaction between coffee consumption and smoking in relation to the risk of MPN. Among women, the p values for interaction ranged from 0.89 to 0.99 for the three MPN subtypes; in men, the p values ranged from 0.39 to 0.67 for the three MPN subtypes. As for the second point discussed by Dr Kawada,2 we recognize that a potentially protective impact of coffee and caffeine on MPN risk could be mediated through anti-inflammatory or other mechanisms. However, our study was designed to assess the possible role of lifestyle factors in the etiology of MPN from an epidemiologic, and not physiologic, perspective. Further studies into the physiologic and molecular mechanisms for MPN pathogenesis are warranted but are beyond the scope of our research. The data that support the findings of our study are available from the NIH-AARP Diet and Health Study. Restrictions apply to the availability of these data, which we obtained with a specific data use agreement for our study. Yours sincerely, Nikolai A. Podoltsev Xiaoyi Wang Rong Wang Jonathan N. Hofmann Linda M. Liao Amer M. Zeidan Ruben Mesa Xiaomei Ma N.A.P. received research funding (institutional) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI Biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals and Kartos Therapeutics. N.A.P. had a consultancy with and received honoraria from Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol-Myers Squib and CTI biopharma. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis and Epizyme. A.M.Z received travel support for meetings from Pfizer, Novartis, Celgene and Trovagene. RM had a consultancy with Novartis, Sierra Oncology, La Jolla and Pharma. R.M. received research funding from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior and CTI.